ScholarIQanswers from OpenAlex & ORCID
Tudor–Eliade Ciuleanu
ResearcherPublications, citations & collaboration network
Tudor–Eliade Ciuleanu is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Tudor–Eliade Ciuleanu have?
ScholarIQindexed works
Tudor–Eliade Ciuleanu has 311 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Tudor–Eliade Ciuleanu have?
ScholarIQcitation count
Tudor–Eliade Ciuleanu has 40,795 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Tudor–Eliade Ciuleanu?
ScholarIQh-index
Tudor–Eliade Ciuleanu has an h-index of 71 in OpenAlex.
What is the i10-index of Tudor–Eliade Ciuleanu?
ScholarIQi10-index
Tudor–Eliade Ciuleanu has an i10-index of 169 in OpenAlex.
What is the ORCID of Tudor–Eliade Ciuleanu?
ScholarIQorcid
The ORCID for Tudor–Eliade Ciuleanu is on the source record.
What is the OpenAlex record for Tudor–Eliade Ciuleanu?
ScholarIQopenalex
The OpenAlex for Tudor–Eliade Ciuleanu is on the source record.
What are the most-cited papers on Tudor–Eliade Ciuleanu?
ScholarIQmost cited works
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Frances A. Shepherd, José Rodrigues Pereira, Tudor–Eliade Ciuleanu, Eng Huat Tan, Vera Hirsh, Sumitra Thongprasert, Daniel Campos, Savitree Maoleekoonpiroj, Michael Smylie, Renato Martins, Maximiliano Van Kooten, Mircea Dediu, B. Findlay, Dongsheng Tu, D. Johnston, Andrea Bezjak, Gary M. Clark, P. Santabárbara, Lesley Seymour
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
Matthew D. Hellmann, Tudor–Eliade Ciuleanu, Adam Płużański, Jong Seok Lee, Gregory A. Otterson, Clarisse Audigier-Valette, Elisa Minenza, Helena Linardou, Sjaak A. Burgers, Pamela Salman, Hossein Borghaei, Suresh S. Ramalingam, Julie R. Brahmer, Martin Reck, Kenneth J. O’Byrne, William J. Geese, George Green, Chang Han, Joseph D. Szustakowski, Prabhu Bhagavatheeswaran, Diane Healey, Yali Fu, Faith E. Nathan, Luis Paz‐Ares
First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer
David P. Carbone, Martin Reck, Luis Paz‐Ares, Ben Creelan, Leora Horn, Martin Steins, Enriqueta Felip, Michel M. van den Heuvel, Tudor–Eliade Ciuleanu, Firas Badin, Neal Ready, T. Jeroen N. Hiltermann, Suresh Nair, Rosalyn A. Juergens, Solange Peters, Elisa Minenza, John Wrangle, Delvys Rodríguez‐Abreu, Hossein Borghaei, George R. Blumenschein, Liza C. Villaruz, Libor Havel, Jana Krejčí, Jesus Corral Jaime, Han Chang, William J. Geese, Prabhu Bhagavatheeswaran, Allen C. Chen, Mark A. Socinski
Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial
Edward B. Garon, Tudor–Eliade Ciuleanu, Óscar Arrieta, Kumar Prabhash, Konstantinos N. Syrigos, Tuncay Göksel, Keunchil Park, Vera Gorbunova, Rubén Dario Kowalyszyn, Joanna Pikiel, Grzegorz Czyżewicz, С. В. Орлов, C. Lewanski, Michael Thomas, Paolo Bidoli, Shaker R. Dakhil, Steven Gans, Joo-Hang Kim, Alexandru Grigorescu, Nina Karaseva, Martin Reck, Federico Cappuzzo, Ekaterine Alexandris, Andreas Sashegyi, Sergey Yurasov, M. Pérol
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study
Josep Tabernero, Takayuki Yoshino, Allen Lee Cohn, Radka Obermannová, G. Bodoky, Rocio García‐Carbonero, Tudor–Eliade Ciuleanu, David C. Portnoy, Eric Van Cutsem, Axel Grothey, Jana Prausová, Pilar García‐Alfonso, Kentaro Yamazaki, Philip R. Clingan, Sara Lonardi, Tae Won Kim, Lorinda Simms, Shao-Chun Chang, Federico Nasroulah